Alexis Nzila currently leads a research group at the King Fahd University of Petroleum and Minerals. One of his key research areas focuses on the understanding the mechanism of antimalarial resistance. From 2008-2010, he was supported by the CGGH to study phenotypic variation in the drug sensitivity of Plasmodium falciparum isolates collected Kilifi District, and to investigate genotype-phenotype associations using genome sequencing data generated on these isolates at the Wellcome Trust Sanger Institute. This work was carried out in collaboration with the KEMRI-Wellcome Trust Research Programme and relates to Alexis’s longstanding interest in the mechanism of action of antimalarial drugs such as lumefantrine, piperaquine and amodiaquine.